Home Tech Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and...

Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)

2

In view of the changing trend of COVID-19 worldwide, Sanyou Biopharmaceuticals took full advantages of its unique R&D platforms, and built a team with ZJ Bio-Tech at the beginning of 2020 to jointly develop SYZJ001. It is an innovative drug against COVID-19 developed in China, and also a leading bispecific antibody drug worldwide.

SYZJ001 is screened from the “Ten-Trillion Innovative Antibody Discovery Platform”, a platform over which Sanyou Biopharmaceuticals has independent intellectual property rights. The drug is composed of a fully-human IgG antibody and a humanized single domain antibody targeting the receptor binding domain (RBD) of SARS-CoV-2’s Spike protein. The two antibodies can non-competitively bind to the antigenic epitopes of RBD proteins, block the binding between the virus and human ACE2 receptors, and efficiently neutralize SARS-CoV-2 and prevent cell infection. 

To be specific, the representative data of the single domain antibody…

Click here for full article…www.prnewswire.com